Provision Language
<p><span style=”text–decoration: underline;”><b>Recitalsb>span>p>
<p><span style=”font–weight: 400;”>Whereas, CEPI’s mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for affected populations during outbreaks;span>p>
<p><span style=”font–weight: 400;”>Whereasspan><b>, b><span style=”font–weight: 400;”>CEPI has entered or may enter in the future into legal agreements with certain third parties (each, a “span><b><i>CEPI Partneri>b><span style=”font–weight: 400;”>”) regarding the funding of development and manufacturing initiatives of vaccines for COVID–19; span>p>
<p><span style=”font–weight: 400;”>Whereasspan><b>, b><span style=”font–weight: 400;”>to further its mission, CEPI desires to advance an interest–free, forgivable, unsecured loan to cover the costs of at risk manufacture of specified quantities of the CpG 1018 adjuvant and to reserve such quantities for purchase by CEPI Partners for use in development and manufacturing of vaccines against COVID–19; […]span>p>
<p><span style=”text–decoration: underline;”><strong>4. Compliance and Regulatorystrong>span>p>
<p>[…]p>
<p><b>4.2 CEPI Third Party Code. b><span style=”font–weight: 400;”>The CEPI Third Party Code is a statement of CEPI’s values and of the policies, practices and principles applicable to recipients of any funds from CEPI.span>p>
<p style=”padding–left: 40px;”>(a) <span style=”font–weight: 400;”>Dynavax acknowledges the statement of CEPI’s values in Section 1 of the Code.span>p>
<p style=”padding–left: 40px;”>(b) <span style=”font–weight: 400;”>Dynavax acknowledges CEPI’s expectation that Dynavax shall adhere to business practices, ethical principles and legal requirements that are at least substantially similar to those described inSections 2 to 10 of the Code.span>p>
<p style=”padding–left: 40px;”>(c) <span style=”font–weight: 400;”>Dynavax shall comply with the requirements for reporting compliance concerns and misconduct to CEPI (Sections 4 and 11 of the Code).span>p>
<p style=”padding–left: 40px;”>(d) <span style=”font–weight: 400;”>Dynavax shall cooperate as may be requested by CEPI in the submission of information related to Project activities and expenditures in accordance with the International Aid Transparency Initiative (Section 12 of the Code).span>p>
<p style=”padding–left: 40px;”>(e) <span style=”font–weight: 400;”>Dynavax shall comply with CEPI’s Equitable Access Policy.span>p>
<p style=”padding–left: 40px;”>(f) <span style=”font–weight: 400;”>To the extent applicable to the Project, Dynavax shall comply with CEPI’s Animals in Research Policy.span>p>
<p style=”padding–left: 40px;”>(g) <span style=”font–weight: 400;”>To the extent applicable to the Project, Dynavax may rely upon its own substantially similar policies and principles so as to comply with: (i) CEPI’s Clinical Trials Policy; (ii) CEPI’s Managing Conflicts Of Interest Policy; (iii) CEPI’s Scientific Integrity Policy; and (iv) CEPI’s Travel and Expenses Policy.span>p>
